Novartis steps in to compete with Mylan’s Epipen

Novartis steps in to compete with Mylan’s Epipen

Source: 
Drug Delivery Business News
snippet: 

Adamis Pharmaceuticals (NSDQ:ADMP) said this week that it inked an exclusive deal with Novartis‘ (NYSE:NVSSandoz unit to distribute and commercialize its Symjepi emergency allergy treatment.